These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 35600862)
1. TCR Coexpression Signature Predicts Immunotherapy Resistance in NSCLC. Wang Y; Liu Y; Li X; Li W; Xue Z; He X; Xiong W; He L; Bai Y Front Pharmacol; 2022; 13():875149. PubMed ID: 35600862 [No Abstract] [Full Text] [Related]
2. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC. Li X; Wang Y; Li X; Feng G; Hu S; Bai Y Front Immunol; 2021; 12():638763. PubMed ID: 34305884 [TBL] [Abstract][Full Text] [Related]
3. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy. Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y Front Immunol; 2021; 12():665002. PubMed ID: 34367132 [TBL] [Abstract][Full Text] [Related]
4. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study. Yan Y; Wang X; Liu C; Jia J BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541 [TBL] [Abstract][Full Text] [Related]
5. Identification of immune-related gene signature for non-small cell lung cancer patients with immune checkpoint inhibitors. Wang L; Han C; Cai C; Wu J; Chen J; Su C Heliyon; 2024 Mar; 10(5):e26974. PubMed ID: 38463866 [TBL] [Abstract][Full Text] [Related]
6. Prognosis of Non-small-cell Lung Cancer Patients With Lipid Metabolism Pathway Alternations to Immunotherapy. Cheng T; Zhang J; Liu D; Lai G; Wen X Front Genet; 2021; 12():646362. PubMed ID: 34335679 [TBL] [Abstract][Full Text] [Related]
7. Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer. Zhang X; Shi X; Zhao H; Jia X; Yang Y Biomed Res Int; 2021; 2021():8864436. PubMed ID: 33860055 [TBL] [Abstract][Full Text] [Related]
8. Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis. Lin X; Deng J; Deng H; Yang Y; Sun N; Zhou M; Qin Y; Xie X; Li S; Zhong N; Song Y; Zhou C Front Immunol; 2021; 12():818492. PubMed ID: 35095920 [TBL] [Abstract][Full Text] [Related]
9. Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma. Li L; Lu G; Liu Y; Gong L; Zheng X; Zheng H; Gu W; Yang L Front Oncol; 2021; 11():658690. PubMed ID: 34150625 [TBL] [Abstract][Full Text] [Related]
10. The Effect of Smoking on the Immune Microenvironment and Immunogenicity and Its Relationship With the Prognosis of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer. Sun Y; Yang Q; Shen J; Wei T; Shen W; Zhang N; Luo P; Zhang J Front Cell Dev Biol; 2021; 9():745859. PubMed ID: 34660603 [No Abstract] [Full Text] [Related]
11. Effect of TTN Mutations on Immune Microenvironment and Efficacy of Immunotherapy in Lung Adenocarcinoma Patients. Wang Z; Wang C; Lin S; Yu X Front Oncol; 2021; 11():725292. PubMed ID: 34513703 [TBL] [Abstract][Full Text] [Related]
12. PTPRO-related CD8 Dong H; Xie C; Yao Z; Zhao R; Lin Y; Luo Y; Chen S; Qin Y; Chen Y; Zhang H Front Immunol; 2022; 13():947841. PubMed ID: 36003382 [TBL] [Abstract][Full Text] [Related]
13. A Novel Pyroptotic and Inflammatory Gene Signature Predicts the Prognosis of Cutaneous Melanoma and the Effect of Anticancer Therapies. Xu Y; Chen Y; Niu Z; Xing J; Yang Z; Yin X; Guo L; Zhang Q; Qiu H; Han Y Front Med (Lausanne); 2022; 9():841568. PubMed ID: 35492358 [TBL] [Abstract][Full Text] [Related]
14. A signature of tumor immune microenvironment genes associated with the prognosis of non‑small cell lung cancer. Li J; Li X; Zhang C; Zhang C; Wang H Oncol Rep; 2020 Mar; 43(3):795-806. PubMed ID: 32020214 [TBL] [Abstract][Full Text] [Related]
15. Fatty Acid Metabolic Signaling Pathway Alternation Predict Prognosis of Immune Checkpoint Inhibitors in Glioblastoma. Liu R; Liang W; Hua Q; Wu L; Wang X; Li Q; Zhong F; Li B; Qiu Z Front Immunol; 2022; 13():819515. PubMed ID: 35251000 [TBL] [Abstract][Full Text] [Related]
16. Wang T; Luo Y; Zhang Q; Shen Y; Peng M; Huang P; Zhou Z; Wu X; Chen K J Thorac Dis; 2022 Mar; 14(3):729-740. PubMed ID: 35399232 [TBL] [Abstract][Full Text] [Related]
17. Effect of mesenchymal-epithelial transition amplification on immune microenvironment and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer. Su S; Lin A; Luo P; Zou J; Huang Z; Wang X; Zeng Y; Cen W; Zhang X; Huang H; Hu J; Zhang J Ann Transl Med; 2021 Sep; 9(18):1475. PubMed ID: 34734027 [TBL] [Abstract][Full Text] [Related]
18. TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Lin A; Zhang H; Meng H; Deng Z; Gu T; Luo P; Zhang J Front Immunol; 2021; 12():667875. PubMed ID: 34603277 [TBL] [Abstract][Full Text] [Related]
19. MYCBP2 expression correlated with inflammatory cell infiltration and prognosis immunotherapy in thyroid cancer patients. Wang G; Miao C; Mo L; Kahlert UD; Wu J; Ou M; Huang R; Feng R; Pang W; Shi W Front Immunol; 2022; 13():1048503. PubMed ID: 36582246 [TBL] [Abstract][Full Text] [Related]
20. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]